Krystal Biotech Inc

Krystal Biotech delivered a standout third quarter, posting earnings per share of $2.66 against a Wall Street consensus of $1.12, a beat of 137.03% that reflected both the accelerating commercial momentum of its gene therapy VYJUVEK and a $31.40 million income tax benefit that meaningfully lifted net income to $79.36 million. Revenue climbed 16.6% year over year to $97.80 million, edging past the $93.42 million consensus estimate by 4.69%, as gross margins expanded to 96% on declining cost of goods sold. The quarter's defining story was VYJUVEK's broadening reach: the FDA updated the therapy's label to cover DEB patients from birth and permit at-home application, while international launches in Germany, France, and Japan opened new commercial fronts that analysts see as the primary catalyst toward a potential $1 billion peak sales target. Cumulative U.S. revenue since launch reached $623.20 million. Looking ahead, the company guided FY 2025 non-GAAP combined R&D and SG&A expenses of $145.00 million to $155.00 million, with pipeline data readouts in cystic fibrosis and other indications expected to provide further catalysts into 2026.